Skip to main content
. 2017 Jun 10;6(7):1614–1626. doi: 10.1002/cam4.1087

Figure 4.

Figure 4

HLA class I or PD‐L1 expression and patient survival. Recurrence‐free survival rates (A) or overall survival rates (B) in PDA patients with high (solid line) or low (dotted line) HLA class I expressing tumors. Recurrence‐free survival rates (C) or overall survival rates (D) in PDA patients with positive (solid line) or negative (dotted line) PD‐L1 expression.